Objective: To determine whether prolonged vascular endothelial growth factor inhibition is toxic to the retina by using pattern electroretinographic imaging in participants with neovascular age-related macular degeneration (AMD).
A

GE-RELATED MACULAR DE-
generation (AMD) is a progressive disease that causes irreversible visual impairment and blindness in nearly 50 million people worldwide. 1, 2 Although geographic atrophy and neovascularization represent the advanced forms of AMD, neovascular AMD is the more aggressive form and accounts for almost 90% of blindness from this disease. 3 It is characterized by choroidal neovascularization (CNV), which is the development of abnormal blood vessels underneath the retina. Vascular endothelial growth factor (VEGF) is a prime mechanism of this process. 4, 5 Targeted therapy against VEGF for neovascular AMD was recently investigated in 2 randomized clinical trials: Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and Anti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD (ANCHOR). 6, 7 Both trials treated participants with ranibizumab (Lucentis; Genentech Inc, South San Francisco, California), a monoclonal antibody that inhibits the isoform VEGF-A, with monthly injections during a 24-month period. The data demonstrate that in patients with subfoveal CNV from AMD, continued intravitreous therapy with ranibizumab leads to stabilization of vision in more than 90% of patients. In addition, at least one-third of patients experienced a significant improvement in vision (Ն15 letters) by the end of the study period. These results led to US Food and Drug Administration approval of ranibizumab (0.5 mg) for the treatment of neovascular AMD. Although these trials also showed that intraocular injections of ranibizumab were well tolerated locally and systemically, retinal function other than visual acuity (VA) was not assessed. Recent data have suggested potential toxicity of anti-VEGF-A therapy to retinal ganglion cells because VEGF is an important mediator of retinal neuroprotection by inhibiting apoptosis and promoting cell survival. 8, 9 In an ischemia-reperfusion model of the rat eye, ischemic preconditioning led to higher levels of VEGF-A. This finding correlated with a decrease in the number of retinal cells undergoing apoptosis. With VEGF-A inhibition, the antiapoptotic effects of preconditioning were reversed, suggesting that VEGF-A is critical in this process. 10 Although evidence exists of VEGFmediated neuroprotection in animal models, minimal clinical data address retinal function after anti-VEGF blockade in ranibizumab-treated human eyes.
Electroretinography (ERG) can be used as a measure of retinal function. Although full-field ERG assesses overall retinal function, pattern ERG (PERG) can record a single response throughout the central visual field. 11, 12 Pattern ERG is a retinal potential evoked when a highcontrast, patterned stimulus is viewed. This is usually performed by alternating black and white checkerboards or stripes, eliciting a positive wave peaking at 50 milliseconds (P50) and a negative wave peaking at 95 milliseconds (N95) after the contrast is reversed. It provides not only a measure of macular function (P50) but also a measurement of ganglion cell function (N95).
11 Multifocal ERG also can be used to evaluate focal responses believed to be cone derived. Although multifocal ERG can be used to assess central retinal function, it does not provide a specific measure of ganglion cell function. 13 However, PERG directly quantifies ganglion cell function. 11 Thus, PERG provides a quantifiable means of assessing macular and ganglion cell function in the context of anti-VEGF therapy. In this study, treatment-naive patients with subfoveal neovascular AMD were treated per label monthly for 6 months with intravitreous ranibizumab and their macular function was evaluated via PERG.
METHODS
Ours was a prospective, single-arm study of intravitreous ranibizumab administered on-label in treatment-naive patients followed up by serial pattern electroretinographic imaging. The institutional review board and Human Research Protection Office at Washington University in St Louis, as well as the study office at Barnes Retina Institute, approved the study.
Inclusion and exclusion criteria are presented in Table 1 . Consented, enrolled study participants received intravitreous injections of 0.5 mg of ranibizumab administered monthly for 6 months. Then pattern electroretinographic imaging was performed at baseline, 1 month, 3 months, and 6 months and graded by a masked trained reader (M.A.B.). The primary outcome measure was the change in pattern electroretinographic imaging (P50 and N95 values) from baseline to 6 months. The secondary outcome measure was the change in VA at 6 months from baseline.
Baseline VA measurement, time-domain optical coherence tomography (OCT), and fluorescein angiography were performed for each patient at the initial visit, as depicted in Table 2 . The VAs were recorded as Snellen equivalents after an Early Treatment of Diabetic Retinopathy Study standardized refraction. The optical coherence tomographic images and fluorescein angiograms were interpreted by the treating physician. The OCT was performed at the final visit, 1 month after the sixth intravitreous injection. Resolution (or lack thereof ) of fluid on optical coherence tomographic imaging was interpreted by the treating physician.
The checkerboard transient PERG was recorded with the Espion E 2 Electrophysiology System (Diagnosys LLC, Boston, Massachusetts) in accordance with the guidelines of the International Society for Clinical Electrophysiology of Vision. 14 The PERGs were recorded using Dawson, Trick, and Litzkow fiber electrodes (Diagnosys LLC) moistened with 1% carboxymethylcellulose sodium placed in the inferior fornix of each eye. Each Dawson, Trick, and Litzkow (DTL) fiber was laid along the top of the lower eyelids so that it contacted the inferior cornea. Fibers were anchored with small adhesive pads near the inner and outer canthi. Reference electrodes were applied with adhesive paste lateral to the outer canthi. An adhesive electrode placed on the forehead served as the ground. The distance between the eye of the patient and the monitor was 30 cm when using the standardized Early Treatment of Diabetic Retinopathy Study refraction. The responses on pattern electroretinographic imaging were recorded, including P50 (derived from macular photoreceptors) and N95 (postphotoreceptor, including the optic nerve), in response to an alternating checkerboard pattern. During recordings, bandpass filter amplifiers included the range from 1 to 100 Hz. The pattern electroretinographic image was obtained using a mean (SD) reversal rate of 4 (0.8) revolutions per second, and the mean of the width and height of the stimulus field was 15°with a check size of 0.8°. The P50 amplitude was measured from the trough of N35 to the peak of P50. The N95 amplitude was measured from the peak of P50 to the trough of N95.
Statistical analyses were performed using the paired t test to analyze VA and pattern electroretinographic variables. P Յ .05 was considered statistically significant. Results were expressed as mean (SD). For analysis, VA was converted to logMAR equivalents and represented as mean VA in Snellen format.
RESULTS
Seventeen patients from the Barnes Retina Institute were enrolled in the study. All patients completed the study per the study design. The mean patient age was 79.6 years (range, 69.5-90.4 years). Most patients were women (14 [82%]), with a roughly equal distribution of CNV lesion types: 8 predominantly classic (47%) and 9 occult (53%) (with or without a classic component) ( Table 3) . By the end of the study period, fluid resolution as determined via OCT was observed in 13 patients (76%).
The results of pattern electroretinographic imaging were deemed uninterpretable for 1 patient and were not incorporated into the statistical analysis. The tracings showed little statistical decrease in P50 or N95 amplitudes during the 6-month period ( Table 4 
COMMENT
Intravitreous ranibizumab has gained widespread use for the treatment of neovascular AMD. Animal studies implicate VEGF as critical in neuroprotection and in the context of the large number of patients receiving anti-VEGF therapy; a study to assess retinal function would be timely. Recent work in animal models also confirms that a significant role for VEGF exists in the prevention of apoptosis of retinal Mü ller cells and photoreceptors. 15 This work shows that systemic VEGF neutralization (for as little as 2 weeks) in mice led to Mü ller cell apoptosis with a decline of retinal function as assessed by ERG. To our knowledge, no conclusive answer exists regarding whether long-term VEGF inhibition in humans with neovascular AMD may lead to retinal cell damage. As reported in the clinical trials cited in this article, central vision in neovascular AMD improves with anti-VEGF therapy; however, this only signifies improvement in less than 1°of the central retina. By comparison, PERG assesses the central 15°and also quantifies ganglion cell function in this area.
To date, studies addressing retinal function after treatment with anti-VEGF therapies in human eyes are limited. Currently, 2 anti-VEGF antibodies are in clinical use (bevacizumab and ranibizumab), and both neutralize an isoform of VEGF (VEGF-A). The full-length anti-VEGF antibody bevacizumab has been prospectively evaluated for retinal toxicity by pattern electroretinographic imaging in a few studies. One study 16 evaluated 35 patients with diabetic macular edema treated with bevacizumab only. No evidence was observed of macular or ganglion cell damage as determined via pattern electroretinographic imaging. This study even showed a significant improvement in P50 and N95 amplitudes during 3 months. These patients were not treated according to a standard protocol, receiving a variable number of injections dependent on the presence of macular edema for only 3 months. Another prospective study 17 evaluated PERG in patients with neovascular AMD treated with photodynamic therapy with verteporfin only or combination photodynamic therapy and intravitreous bevacizumab. The results revealed no evidence of retinal damage as determined by pattern electroretinographic imaging with significant improvement in P50 amplitudes from baseline in both treatment groups. This study was limited by the short follow-up time of only 1 month.
Retinal function data for ranibizumab also are limited. Lü ke and colleagues 18 studied ranibizumab and its effects on retinal function with an ex vivo model of bovine retinas. Postmortem bovine eyes were superfused with supratherapeutic concentrations of ranibizumab (equivalent to a 1-mg injection), and subsequent electroretinographic recordings were performed. After a 45-minute perfusion of ranibizumab, the a-wave amplitude was only reduced by 4% with no statistical difference from baseline. Although this finding provides interesting ex vivo animal data, it is important to record retinal function in vivo by monitoring retinal function in patients receiving multiple injections for an extended period. 
